Navigation Links
Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
Date:6/1/2009

SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical trial will include patients with advanced colorectal, thyroid, non-small cell lung, hepatocellular, head and neck, or renal cell cancers who have failed to respond to at least one line of therapy.

Enrolled patients will receive 200 mg of R788 twice a day and will be monitored to measure a variety of clinical responses as well as drug safety. Patients will continue to receive R788 in 28-day treatment cycles until disease progression, or patient or physician withdrawal occurs. The NCI will conduct the clinical trial, Rigel will supply study drug and will receive clinical data and trial results.

"We value the NCI's expertise and support in exploring the potential of R788 in treating these solid tumors," said Elliott Grossbard, M.D., executive vice president and chief medical officer of Rigel. "These results may provide another path for further expanding R788's therapeutic potential," he added.

Rigel is presently conducting two Phase 2b clinical trials with R788, known as TASKi2 and TASKi3, in patients with rheumatoid arthritis. Results from these trials are expected in July of this year. In addition, the company has an ongoing Phase 2 clinical trial of R788 in patients with peripheral T-cell lymphoma and reported favorable results from a Phase 2 clinical trial of R788 in the treatment of patients with certain B-cell lymphomas in June 2008.

About Rigel (www.Rigel.com)

Rigel is a clin
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers
2. MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa
3. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
6. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
7. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. National Medical Interpreter Certification Testing Enters Pilot Phase
10. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
11. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Dr. Allen Kamrava, colorectal ... launch of a new website dedicated to the diagnosis ... be found at DrKamrava.com . , “With this ... a knowledgeable and trustworthy source for various colorectal ... hemorrhoids, fissures, gallstones, colon cancer, hernias, or more, patients ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... online marketing training course that takes a comprehensive, step-by-step ... scale an online marketing venture has just been released ... Hendricks. , “In the internet marketing world if you’re ... Hendricks. “And a lot of people simply give up ...
(Date:7/22/2014)... 2014 Eating certain foods can not only ... according to two of the world’s top cosmetic dentists. ... of the Anacapa Dental Art Institute in Oxnard and Woodland ... of one’s teeth. They are specially trained to replace missing ... not seeing a dentist regularly, and about two-thirds of the ...
(Date:7/22/2014)... Kirby Lester, LLC, the leading pharmacy automation ... functionality to perform a trackable double-count for any prescription ... double-count of controlled medications is required, the KL1Plus allows ... a second count of any tablet or capsule order. ... second count up to 10 years. This function is ...
(Date:7/22/2014)... 22, 2014 Industry-leading health business information ... release of Specialty Pharmacy Trends and Strategies: 2014 ... provides a comprehensive overview of the current state of ... strategies and tactics for:, , Specialty ... utilization concerns — including details of coinsurance levels by ...
Breaking Medicine News(10 mins):Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 2Health News:Los Angeles Doctor Launches Brand New Website for Colorectal Surgery and Treatment 3Health News:Info Cash 2.0: Review Of Chris Carpenter’s Online Marketing Training Released 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 2Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 3Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 4Health News:Ventura’s Best Cosmetic Dentists Offer 4 Tips for Improving Dental Health Through Nutrition 5Health News:Kirby Lester KL1Plus Pharmacy Automation Perfect for Double-Counting & Tracking Prescriptions from Any Pharmacy Robot 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2
... radiation dose was equivalent to 113 chest X-rays, study finds ... of patients who have abdominal/pelvic CT scans receive additional unnecessary ... say. , In the study, 978 CT abdominal and pelvic ... 91 years. Most of the patients were 30 to 50 ...
... , LOS ANGELES, Nov. 30 Menopause ... brings with it a host of uncomfortable symptoms that negatively impact ... gain , night sweats and lethargy are just some of the ... and symptoms can show up a full ten years before ...
... , CARDIFF, Calif., Nov. 30 Jedi Mind, ... Company,s first thought-controlled game is complete and available for purchase. The ... user to play the game with the power of their mind ... be sold online at a price of $49 and can be ...
... CHARLTON, Mass., Nov. 30 Harrington Physician Services (HPS) is ... Devine, Leah Doret, Elizabeth Fuller and Monika Mathur to its ... Charlton-based physicians, coming from the Fallon Clinic, will soon join ... medical office building under construction at 10 North Main Street, ...
... , MINNEAPOLIS, Nov. 30 The Eject Helmet Removal System ... Top Fuel, Funny Car, Pro Stock Car and Pro Stock Motorcycle classes ... as well as for Top Alcohol dragster and Top Alcohol Funny Car ... is the only product that allows medical caregivers at race tracks and ...
... discussion in the scientific community, the Institute for Quality ... for evaluating the relation between cost and benefit. The ... certain commissions awarded by the Federal Joint Committee (G-BA). ... on recommendations to the GKV-Spitzenverband [National Association of Health ...
Cached Medicine News:Health News:CT Scan Patients May Get Unnecessary Imaging 2Health News:Anti-Aging Institute of California Offers New Natural Solution for Menopause Symptoms 2Health News:First Thought-Controlled Game Complete From Jedi Mind, Inc. 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 2Health News:Family Practice Physicians Martin Devine, Leah Doret, Elizabeth Fuller and Monika Mathur Join Harrington Physician Services in Charlton 3Health News:National Hot Rod Association Mandates Eject Helmet Removal System for 2010 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5
(Date:7/21/2014)... -- Champions Oncology (OTC: CSBR), a company engaged in the ... the development and use of oncology drugs, today announced ... the fourth quarter and fiscal year ended April 30, ... The company will host a conference call ... EDT (1:30 p.m. PDT). To participate in the call, ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... 2014 A ... biosimilars/follow-on-biologics market (types, applications and geography) - Size, ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... reach $35 billion by 2020 from the estimated ... regulatory pathways in developed markets and higher efficacy ...
Breaking Medicine Technology:EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 2Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 3Biosimilars/Follow-on-Biologics Market is Expected to Reach $35 Billion, Globally, by 2020 4
... ANA598 demonstrates favorable preclinical antiviral, metabolic, ... preliminary toxicologic properties, SAN DIEGO, Sept. 11 ... preclinical data today on ANA598, a,non-nucleoside inhibitor of ... the 14th International Symposium on Hepatitis C Virus ...
... have or have,ever had chronic heartburn, you may be ... severe gastroesophageal reflux disease,(GERD). Barrett,s esophagus has been recognized ... esophagus, the seventh deadliest cancer in men in,the United ... in the lining of the,esophagus, which can progress to ...
Cached Medicine Technology:Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer 2
... come back with better resolution, accuracy and ... 25 or 31 rings (same as TMS-1), ... provides high accuracy & repeatability. The small ... & provides extensive corneal coverage. The low ...
... Pachycam is the first compact and ... The OCULUS Pachycam has automatic ... pressure) in accordance with Shah or ... The OCULUS Pachycam is non-contact ...
World's first commercially available vacuum assisted biopsy device for MRI....
... stereotactic, ultrasound and MRI-guided vacuum assisted breast ... Use the patented, FDA-cleared ATEC system for ... advanced method of breast biopsy. Its compassionate ... who trust YOU.,12 Gauge Handpieces: Useful for ...
Medicine Products: